Komipharm International코미팜
041960 · KOSDAQ · ₩041960 · 코미팜
₩9,070▲ ₩320 (3.66%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩52B | ₩59B | ₩43B | ₩40B | ₩36B |
| Cost of sales | ₩35B | ₩37B | ₩30B | ₩28B | ₩25B |
| Gross profit | ₩17B | ₩22B | ₩13B | ₩11B | ₩11B |
| Operating income | ₩2B | ₩6.2B | −₩6.3B | −₩3.8B | −₩5.3B |
| Net income | −₩8B | ₩15B | −₩5.9B | −₩7.5B | −₩5.9B |
| Net income to shareholders | −₩7.2B | ₩13B | −₩4B | −₩6.5B | −₩4.5B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩134B | ₩123B | ₩119B | ₩112B | ₩115B |
| Current assets | ₩68B | ₩60B | ₩50B | ₩43B | ₩41B |
| Cash and equivalents | ₩28B | ₩12B | ₩15B | ₩11B | ₩12B |
| Total liabilities | ₩62B | ₩57B | ₩59B | ₩46B | ₩43B |
| Current liabilities | ₩53B | ₩46B | ₩52B | ₩41B | ₩26B |
| Borrowings | ₩40B | ₩43B | ₩45B | ₩38B | ₩33B |
| Total equity | ₩72B | ₩66B | ₩60B | ₩66B | ₩72B |
| Shareholders' equity | ₩70B | ₩62B | ₩56B | ₩61B | ₩66B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩622M | ₩8.8B | −₩2.8B | −₩1.8B | −₩1.3B |
| Capital spending | ₩3.1B | ₩1B | ₩637M | ₩848M | ₩813M |
| Free cash flow | −₩3.7B | ₩7.8B | −₩3.4B | −₩2.7B | −₩2.1B |
Consolidated where available. Amounts in won.
Also known as: Komipharm International / 코미팜 / 041960 / KRX:041960
Source: KRX statistical information